OBLN Obalon Therapeutics

Obalon To Present at Two Upcoming Institutional Investor Conferences

Obalon To Present at Two Upcoming Institutional Investor Conferences

SAN DIEGO, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: ), a weight loss solutions company focused on commercializing the Obalon Balloon System, the first and only FDA-approved swallowable, gas-filled intra-gastric balloon for weight loss, announces that Bill Plovanic, President and Chief Executive Officer, will present corporate overviews at the following investor conferences:

Stifel 2019 Healthcare Conference                                                                                

Wednesday, November 20, 2019, Presentation time 9:10am ET                     

Lotte New York Palace Hotel, New York City                                                                                                         

Webcast Available at:

Canaccord Genuity Medical Technologies & Diagnostics Forum

Thursday, November 21, 2019, Presentation time 2:00pm ET                                                           

The Westin Grand Central Hotel, New York City                                                                                                           

Webcast Available at:

Live audio webcasts of the presentation can be accessed through the links above. Replays of the webcasts will be available for 90 days following each presentation.

About Obalon Therapeutics, Inc.

Obalon Therapeutics, Inc. (NASDAQ:) is a San Diego-based company focused on developing and commercializing novel technologies for weight loss. For more information, please visit .

For Obalon Therapeutics, Inc.

Investor Contact:

Bill Plovanic

President & Chief Executive Officer

Obalon Therapeutics, Inc.

Office:

 

EN
14/11/2019

Underlying

OBLNObalon Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Obalon Therapeutics

 PRESS RELEASE
Free
OBLN Obalon Therapeu...

Obalon Announces First Quarter 2021 Financial Results

Obalon Announces First Quarter 2021 Financial Results SAN DIEGO, May 12, 2021 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the first quarter ended March 31, 2021. On January 19, 2020 the Company signed a definitive agreement for a merger with ReShape Lifesciences Inc. Financial results for the first quarter of 2021 Revenue for the first quarter of 2021 was no...

May 12, 2021 1 EN
 PRESS RELEASE
Free
OBLN Obalon Therapeu...

Obalon Announces Fourth Quarter and Full Year 2020 Financial Results

Obalon Announces Fourth Quarter and Full Year 2020 Financial Results SAN DIEGO, March 12, 2021 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the fourth quarter and full year ended December 31, 2020. On November 10, 2020, the Company signed a non-binding term sheet for merger with ReShape Lifesciences Inc. and, on January 20, 2021, announced that a definitive agreeme...

March 13, 2021 1 EN
 PRESS RELEASE
Free
OBLN Obalon Therapeu...

Obalon Announces Third Quarter 2020 Financial Results

Obalon Announces Third Quarter 2020 Financial Results SAN DIEGO, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the third quarter ended September 30, 2020. Financial results for the third quarter of 2020 Revenue for the third quarter of 2020 was $44,000, compared to $0.3 million for the third quarter of 2019, with the decrease primarily due to the sus...

November 6, 2020 1 EN
 PRESS RELEASE
Free
OBLN Obalon Therapeu...

Obalon Announces Consulting Agreement As Part of Strategy To Seek Cove...

Obalon Announces Consulting Agreement As Part of Strategy To Seek Coverage and Reimbursement for The Obalon Balloon System SAN DIEGO, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (Nasdaq: OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that it has executed a consulting agreement with Blue Ox Healthcare Partners, LLC, a private equity firm focused on commercial-ready companies bringing technology enabled innovation to healthcare, especially those invo...

August 13, 2020 1 EN
 PRESS RELEASE
Free
OBLN Obalon Therapeu...

Obalon Announces Second Quarter 2020 Financial Results

Obalon Announces Second Quarter 2020 Financial Results SAN DIEGO, July 30, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the second quarter ended June 30, 2020. Financial results for the second quarter of 2020 Revenue for the second quarter of 2020 was $0.7 million, compared to $0.4 million for the second quarter of 2019, primarily due to reversals of revenue...

July 30, 2020 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch